Redeye’s view on Dignitana is generally unchanged. The sales momentum continued in the quarter with better cost control. The gross margin bounced back to the normal range after Q4. The US market. | May 26, 2023
‒ Voruciclib alone or in combination with venetoclax was generally well tolerated with no significant myelosuppression ‒
– Encouraging preliminary efficacy signal demonstrated. | May 23, 2023
Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical. | May 23, 2023
1 The Company reports its financial results in accordance with U.S. generally accepted accounting principles . As used in this table and throughout this earnings release, adjusted operating income . | May 22, 2023